Vanda Agrees to Settle Over Allegations of False, Misleading Statements

Vanda Pharmaceuticals has agreed to pay $11.5 million to settle a class action lawsuit over alleged false or misleading statements.

The complaint filed in February 2019 accused the company of promoting off-label uses of two drugs — Fanapt, a medication used to treat adult patients with schizophrenia, and Hetlioz, a medication approved for the treatment of non-24-hour sleep-wake disorder.

The company had also got into trouble with the federal government, receiving a warning letter from the FDA October 2018 following a review of the company’s website.

Vanda denied any wrongdoing in the lawsuit.